NCT06316843View on ClinicalTrials.gov

Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

October 15, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Long COVIDPASC Post Acute Sequelae of COVID 19
Interventions
DRUG

Valacyclovir celecoxib dose 1

1500 mg valacyclovir 200 mg celecoxib taken two times a day

DRUG

Valacyclovir celecoxib dose 2

750 mg valacyclovir 200 celecoxib mg taken two times a day

DRUG

Placebo

Placebo capsules colored matched to investigational product taken two times a day

Trial Locations (1)

84102

Bateman Horne Center, Salt Lake City

All Listed Sponsors
lead

Bateman Horne Center

OTHER

NCT06316843 - Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2 | Biotech Hunter | Biotech Hunter